Combinatorial strategies to target RAS-driven cancers
N Perurena, L Situ, K Cichowski - Nature Reviews Cancer, 2024 - nature.com
Although RAS was formerly considered undruggable, various agents that inhibit RAS or
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …
specific RAS oncoproteins have now been developed. Indeed, the importance of directly …
[HTML][HTML] Cancer cell-intrinsic PD-1: Its role in Malignant progression and immunotherapy
M Chen, L Bie, J Ying - Biomedicine & Pharmacotherapy, 2023 - Elsevier
Programmed cell death protein-1 (PD-1), also called CD279, is coded by the PDCD1 gene
and is constitutively expressed on the surface of immune cells. As a receptor and immune …
and is constitutively expressed on the surface of immune cells. As a receptor and immune …
The antitumor activities of anti-CD47 antibodies require Fc-FcγR interactions
While anti-CD47 antibodies hold promise for cancer immunotherapy, early-phase clinical
trials have shown limited clinical benefit, suggesting that CD47 blockade alone might be …
trials have shown limited clinical benefit, suggesting that CD47 blockade alone might be …
Disulfiram/copper induces immunogenic cell death and enhances CD47 blockade in hepatocellular carcinoma
X Gao, H Huang, C Pan, Z Mei, S Yin, L Zhou, S Zheng - Cancers, 2022 - mdpi.com
Simple Summary The combination of disulfiram and copper is a novel anti-cancer drug
under clinical development for the treatment of several tumor types including hepatocellular …
under clinical development for the treatment of several tumor types including hepatocellular …
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
T Zeller, IA Münnich, R Windisch, P Hilger… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint blockade is a compelling approach in tumor immunotherapy. Blocking
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
Anti-tumor strategies by harnessing the phagocytosis of macrophages
SY Li, YL Guo, JW Tian, HJ Zhang, RF Li, P Gong… - Cancers, 2023 - mdpi.com
Simple Summary Macrophages are the “big eaters” of the immune system who are in charge
of engulfing undesirable substances. Macrophages are vital for the human body as they are …
of engulfing undesirable substances. Macrophages are vital for the human body as they are …
Nanomedicine Remodels Tumor Microenvironment for Solid Tumor Immunotherapy
Y Guo, P Hu, J Shi - Journal of the American Chemical Society, 2024 - ACS Publications
Although immunotherapy is relatively effective in treating hematological malignancies, their
efficacy against solid tumors is still suboptimal or even noneffective presently. Compared to …
efficacy against solid tumors is still suboptimal or even noneffective presently. Compared to …
Immunological nanomaterials to combat cancer metastasis
Metastasis causes greater than 90% of cancer-associated deaths, presenting huge
challenges for detection and efficient treatment of cancer due to its high heterogeneity and …
challenges for detection and efficient treatment of cancer due to its high heterogeneity and …
Targeting macrophages for tumor therapy
Y Wang, A Barrett, Q Hu - The AAPS Journal, 2023 - Springer
Macrophages, as one of the most abundant tumor-infiltrating cells, play an important role in
tumor development and metastasis. The frequency and polarization of tumor-associated …
tumor development and metastasis. The frequency and polarization of tumor-associated …
Modulating the immune system as a therapeutic target for myelodysplastic syndromes and acute myeloid leukemia
CM Putnam, L Kondeti, MBA Kesler… - Biochemistry and Cell …, 2023 - cdnsciencepub.com
Modulating the immune system to treat diseases, including myeloid malignancies, has
resulted in the development of a multitude of novel therapeutics in recent years …
resulted in the development of a multitude of novel therapeutics in recent years …